miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug
- 264 Downloads
Epithelial to mesenchymal transition (EMT) is a critical step in the growth and dissemination of malignant diseases, including breast cancer. It is known that microRNAs (miRNAs) play important roles in the regulation of tumor properties in cancers. However, whether miR-497 contributes to EMT in breast cancer cells remains unknown. Our study demonstrated that the expression of miR-497 was significantly decreased in human breast cancer cell lines and breast cancer specimens. In breast cancer cells, EMT was inhibited and promoted by the over-expression as well as depletion of miR-497, respectively. Dual-Luciferase ReporterAassay confirmed that Slug was a direct target of miR-497. The upregulation of miR-497 in breast cancer cells suppressed cell proliferation and induced apoptosis both in vitro and in vivo. Correlation analysis indicated that miR-497 was highly negatively correlated with Slug expression in breast cancer specimens. The knockdown of Slug expression in breast cancer cells significantly suppressed cell proliferation and promoted apoptosis. Our results suggested that the expression of miR-497 is significantly correlated with EMT in breast cancer cells by regulating Slug at the transcriptional as well as translational levels. Therefore, targeting miR-497 may provide a novel strategy for the treatment of breast cancer.
KeywordsBreast cancer miR-497 EMT Slug Apoptosis
epithelial to mesenchymal transition
quantitative reverse transcription polymerase chain reaction
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
cell counting kit-8
Compliance with ethical standards
The ethic committee of The Second Affiliated Hospital & Yuying Children’ s Hospital of Wenzhou Medical University had approved this trial in October, 2012. Informed consent was obtained from all individual participants included in this study. This clinical trial had been registered on Clinical Trials.gov (NCT01336245).
Conflicts of interest